<root>
	<PMID Version="1">26430725</PMID>
	<Summary>
		1: Bjorklund CC, Lu L, Kang J, Hagner PR, Havens CG, Amatangelo M, Wang M, Ren Y,Couto S, Breider M, Ning Y, Gandhi AK, Daniel TO, Chopra R, Klippel A, ThakurtaAG. Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underliesdifferential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4. Blood Cancer J. 2015 Oct 2;5:e354. doi:10.1038/bcj.2015.66. PubMed PMID: 26430725.
	</Summary>
</root>
